Opendata, web and dolomites

ATx201

A novel class of antibiotics for treatment of infected atopic dermatitis: an innovative solution for a significant unmet medical need

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ATx201" data sheet

The following table provides information about the project.

Coordinator
UNION THERAPEUTICS AS 

Organization address
address: TUBORG HAVNEVEJ 18
city: HELLERUP
postcode: 2900
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website http://www.antibiotx.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-08-01   to  2016-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNION THERAPEUTICS AS DK (HELLERUP) coordinator 50˙000.00

Map

 Project objective

AntibioTx is advancing a chemical class of compounds to be approved and used for the first time to treat bacterial infections. The class is based on an easy to synthesize chemical scaffold, which enables broad applicability across topical and systemic indications. AntibioTx discovered that compounds from this class overcome current resistance problems such as methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant enterococci and resistance towards all topical antibiotics. The class also exhibits extraordinarily strong ability to delay the onset of de novo resistance compared to marketed antibiotics. Finally, the compound class benefits from a proven human safety profile due to decades of safe oral use for non-bacterial purposes. The antibacterial properties of the class are novel and have been patent protected by AntibioTx. ATx201 is a lead candidate from this novel class of antibiotics and has the potential to fundamentally change thel approach to managing dermatological infections by providing an effective topical alternative to systemic treatments. ATx201 is being developed for treatment of infected atopic dermatitis a disease affecting >50 million patients worldwide associated with significant comorbidity. The market for treatment of infected atopic dermatitis is characterized by off-label use of topical and systemic antibiotics. Topical treatment is preferred by physicians; however, antibiotic resistance is rendering the leading topical antibiotics ineffective. As a result patients and physicians are seeking alternative treatments. ATx201 has substantial competitive advantages to current leading topical antibiotics. In particular ATx201 benefits from a wide spectrum of effect and very favourable resistance evolution properties.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ATX201" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ATX201" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

EXPERT (2019)

EXpanding Platforms for Efficacious mRNA Therapeutics

Read More